This Week in Pulmonary — Jun 5, 2026

Welcome to This Week in Pulmonary. This week we're covering 9 notable papers spanning advances in COPD management, new insights into rare and genetic lung diseases, and the intersection of pulmonology with systemic disease and public health. Let's dive in.

First, we'll address a central challenge in advanced COPD: managing persistent dyspnea. A new multicenter, cross-over randomized trial in The European Respiratory Journal questions the role of opioids for this indication [7]. The study enrolled 58 patients with advanced COPD and an mMRC score of 3 or higher, despite optimal therapy. Participants cycled through two-week periods of transdermal fentanyl, oral morphine, and placebo. The key finding was that neither transdermal fentanyl nor oral morphine showed any significant benefit over placebo for the primary endpoint of mean daily dyspnea. There were also no differences in worst daily dyspnea, health status, anxiety, or sleep quality. The trial had a high dropout rate, primarily due to exacerbations and side effects, reinforcing the challenges of studying this fragile population, but the conclusion is stark: in this trial, low-dose opioids did not palliate chronic breathlessness in severe COPD. While we grapple with symptomatic treatment, other research is exploring the fundamental drivers of emphysema, looking far beyond the lungs. A study in Respiratory Research investigates the gut-lung axis [5]. Researchers compared the gut microbiota and metabolites of 78 individuals with a smoking history, categorizing them into non-emphysema, non-severe emphysema, and severe emphysema groups. They found significant differences, with lower levels of acetic acid in patients with severe emphysema and a greater abundance of Prevotellaceae and Megasphaera in those without emphysema. More compellingly, in a mouse model, fecal microbiota transplantation from human donors with severe emphysema actually worsened smoke-induced lung pathology, whereas transplantation from donors without emphysema attenuated it. This suggests the gut microbiome may modulate emphysema development, opening a potential future therapeutic avenue. Rounding out our COPD theme, a paper in Thorax looks at where research on procedural interventions should go next [1]. Using a James Lind Alliance methodology that involved both people with COPD and healthcare professionals, investigators established the top 10 research priorities for lung volume reduction treatments. These priorities focus on critical unanswered questions regarding how to best identify, assess, and optimize patients before a procedure, how the procedures themselves are conducted, and how post-procedure care should be organized, providing a clear roadmap for future clinical trials in this area.

Turning to rare and genetic lung diseases, a new study in Chest provides valuable guidance on diagnosing primary ciliary dyskinesia, or PCD, in adults [3]. Because the classic diagnostic criteria were validated in children, their accuracy in adults has been less certain. This retrospective analysis of 156 adults referred for possible PCD found that the presence of at least two of the four key clinical criteria—modified as year-round wet cough or nasal congestion since early childhood, neonatal respiratory distress, or organ laterality defects—had a high sensitivity of 95% and specificity of 88%. The most significant finding, however, was that adding infertility or subfertility as a fifth criterion boosted the sensitivity for diagnosing PCD to a perfect 100%, with only a minimal drop in specificity to 84%. The study also confirmed that a low nasal nitric oxide measurement is a powerful screening tool in adults, with 88% sensitivity and 98% specificity. The clear takeaway is that clinicians should be assessing for these five features in adults with a suspicious history and using nasal nitric oxide to screen for PCD when available. From diagnosis to long-term treatment, we now have more data on the effects of Elexacaftor/tezacaftor/ivacaftor, or ETI, in cystic fibrosis. A study in Respiratory Medicine looked at outcomes in 60 patients after one to four years of therapy [2]. Clinically, the therapy led to sustained improvements in lung function. On a cellular level, ETI significantly increased the ability of monocytes to phagocytose Pseudomonas aeruginosa, bringing it to levels seen in people without CF. However, the researchers also noted that the expression of the CFTR protein and its channel function in these monocytes remained significantly lower than in non-CF controls, suggesting the clinical benefit is accompanied by a partial, not complete, restoration of cellular function. Finally, in the rare pediatric condition of post-infectious bronchiolitis obliterans, or PIBO, a trial in The European Respiratory Journal explored a non-pharmacologic intervention [8]. This randomized controlled trial assigned 51 children and adolescents to either a 16-week, home-based, remotely-supervised high-intensity interval training program or a control group. The HIIT program was effective, resulting in significant improvements in peak oxygen consumption and functional capacity, as measured by the 30-second Sit-to-Stand test, compared to controls. This provides evidence for a feasible and effective home-based exercise program to improve cardiorespiratory fitness in this specific young patient population.

Our final theme looks at how pulmonary medicine intersects with systemic disease and public health. First, a major pooled analysis in The Lancet provides new evidence for the use of finerenone in patients with chronic kidney disease, a common comorbidity in our patients [4]. This individual participant data meta-analysis combined three large randomized trials, including over 14,500 participants. The results were robust: Finerenone reduced the risk of a composite kidney outcome, including progression to kidney failure, by 24 percent. It also cut the risk of a composite cardiovascular outcome—hospitalization for heart failure or cardiovascular death—by 20 percent. Furthermore, it was associated with a 12 percent reduction in all-cause mortality. Crucially, these benefits were consistent across a wide spectrum of patients, regardless of their diabetes status, the cause of their kidney disease, their baseline kidney function, or their use of SGLT2 inhibitors. While hyperkalemia was more frequent with finerenone, severe cases leading to hospitalization were rare. The authors conclude that these findings support using finerenone as a foundational therapy for a broad range of patients with CKD. Finally, two commentaries highlight crucial public health and policy issues. In Thorax, an editorial discusses the United Kingdom's 2026 Tobacco and Vapes Act, signaling a move towards a 'tobacco endgame' [6]. And in The European Respiratory Journal, a 'call to action' from the IRIS group addresses the need to ensure continued access to essential inhaled respiratory medications amidst environmental concerns and the transition to greener propellants [10]. Both pieces underscore the critical role of policy and advocacy in pulmonary health—from aggressive tobacco control to navigating the complex shift towards more environmentally friendly inhalers without compromising patient care. They serve as a reminder that our responsibilities extend beyond the clinic to the broader public health landscape.

If you only have time for one paper this week, make it the trial on opioids for dyspnea in COPD from The European Respiratory Journal [7]. It provides a clear, high-quality answer to a frequent clinical question, demonstrating no benefit for either fentanyl or morphine over placebo for chronic breathlessness in this population.

Here are the key takeaways from this week in Pulmonary. First, for patients with advanced COPD and persistent dyspnea, neither low-dose transdermal fentanyl nor oral morphine appears to be more effective than placebo, according to a new randomized controlled trial [7]. Second, when evaluating adults for possible Primary Ciliary Dyskinesia, add infertility or subfertility to the four key pediatric clinical criteria. The presence of two or more of these five features is highly sensitive for PCD, and a low nasal nitric oxide level is highly specific [3]. Third, in patients with a wide range of chronic kidney disease, the non-steroidal MRA finerenone significantly reduces the risk of both kidney disease progression and major adverse cardiovascular events, supporting its use as a foundational therapy in this comorbid population [4]. And finally, in children and adolescents with post-infectious bronchiolitis obliterans, a remotely supervised, home-based high-intensity interval training program can effectively improve cardiorespiratory fitness and functional capacity [8].

That's your roundup for This Week in Pulmonary. The full transcript and references are available on the episode page in your AudioScholar library. This is an AI-curated summary — for clinical decisions, always consult primary sources and current guidelines. See you next week.

This is an automated summary generated by artificial intelligence, which can make mistakes. Always review the original source materials.